Fatty Liver Disease, Women, and Aldosterone: Finding a Link in the Jackson Heart Study

Overview

Journal J Endocr Soc

Specialty Endocrinology

Date 2017 Dec 22

PMID 29264501

Citations 8

Authors

Aditi Kumar

Chad Blackshear

Jose S Subauste

Nazanene H Esfandiari

Elif Arioglu Oral

Angela R Subauste

Affiliations

Soon will be listed here.

Abstract

Context: Fatty liver disease is one of the most common forms of chronic liver disease. The renin-angiotensin-aldosterone system has been implicated in the pathogenesis of fatty liver.

Objective: Determine the relationship between fatty liver and aldosterone in a large cohort study.

Design: Community-based, observational cohort study of African Americans.

Setting: The original Jackson Heart Study cohort enrolled African American participants from the Jackson, Mississippi, metropolitan area in Hinds, Madison, and Rankin Counties.

Participants: Our study population consisted of 2507 Jackson Heart Study participants (1625 women and 882 men) who had liver attenuation measured per computed tomography scans, had aldosterone measurements, and were not taking angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or mineralocorticoid receptor antagonists.

Intervention: There was no intervention.

Main Outcome Measure: Liver attenuation on computed tomography scans.

Results: Univariate regression analysis demonstrated a statistically significant correlation between aldosterone levels and liver attenuation. Each doubling of aldosterone was associated with 1.08 Hounsfield unit decrease (95% confidence interval, 1.47 to -0.69, < 0.001). A multivariable model adjusted for body mass index, age, alcohol intake, and homeostatic model assessment of insulin resistance determined that the association was statistically significant only for women.

Conclusion: Our data demonstrate a positive association between aldosterone levels and fatty liver in African American women.

Citing Articles

Associating plasma aldosterone concentration with the prevalence of MAFLD in hypertensive patients: insights from a large-scale cross-sectional study.

Shen D, Cai X, Hu J, Song S, Zhu Q, Ma H Front Endocrinol (Lausanne). 2024; 15:1451383.

PMID: 39363897 PMC: 11446807. DOI: 10.3389/fendo.2024.1451383.

Adiposity, aldosterone and plasma renin activity among African Americans: The Jackson Heart Study.

Lee G, Kluwe B, Zhao S, Kline D, Nedungadi D, Brock G Endocr Metab Sci. 2023; 11.

PMID: 37475849 PMC: 10358448. DOI: 10.1016/j.endmts.2023.100126.

Relationship Between Plasma Aldosterone Concentrations and Non-Alcoholic Fatty Liver Disease Diagnosis in Patients with Hypertension: A Retrospective Cohort Study.

Hu J, Cai X, Zhu Q, Heizhati M, Wen W, Luo Q Diabetes Metab Syndr Obes. 2023; 16:1625-1636.

PMID: 37304667 PMC: 10257476. DOI: 10.2147/DMSO.S408722.

Nonalcoholic Fatty Liver Disease and Endocrine Axes-A Scoping Review.

Von-Hafe M, Borges-Canha M, Vale C, Leite A, Neves J, Carvalho D Metabolites. 2022; 12(4).

PMID: 35448486 PMC: 9026925. DOI: 10.3390/metabo12040298.

Non-Alcoholic Fatty Liver Disease and Hypokalemia in Primary Aldosteronism Among Chinese Population.

Chen Y, Chen X, Chen Q, Yu C Front Endocrinol (Lausanne). 2021; 12:565714.

PMID: 33967948 PMC: 8101285. DOI: 10.3389/fendo.2021.565714.

References

Loomba R, Sanyal A . The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013; 10(11):686-90. DOI: 10.1038/nrgastro.2013.171. View

Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K . Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004; 40(5):1222-5. DOI: 10.1002/hep.20420. View

Bertolotti M, Lonardo A, Mussi C, Baldelli E, Pellegrini E, Ballestri S . Nonalcoholic fatty liver disease and aging: epidemiology to management. World J Gastroenterol. 2014; 20(39):14185-204. PMC: 4202348. DOI: 10.3748/wjg.v20.i39.14185. View

Lonardo A, Trande P . Are there any sex differences in fatty liver? A study of glucose metabolism and body fat distribution. J Gastroenterol Hepatol. 2000; 15(7):775-82. DOI: 10.1046/j.1440-1746.2000.02226.x. View

Tota-Maharaj R, Blaha M, Zeb I, Katz R, Blankstein R, Blumenthal R . Ethnic and sex differences in fatty liver on cardiac computed tomography: the multi-ethnic study of atherosclerosis. Mayo Clin Proc. 2014; 89(4):493-503. PMC: 4410019. DOI: 10.1016/j.mayocp.2013.12.015. View

Lonardo A, Carani C, Carulli N, Loria P . 'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. J Hepatol. 2006; 44(6):1196-207. DOI: 10.1016/j.jhep.2006.03.005. View

Hirata T, Tomita K, Kawai T, Yokoyama H, Shimada A, Kikuchi M . Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). Int J Endocrinol. 2013; 2013:587140. PMC: 3755443. DOI: 10.1155/2013/587140. View

Paschos P, Tziomalos K . Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment. World J Hepatol. 2013; 4(12):327-31. PMC: 3554795. DOI: 10.4254/wjh.v4.i12.327. View

Musso G, Gambino R, Cassader M, Pagano G . A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010; 52(1):79-104. DOI: 10.1002/hep.23623. View

10.

Bild D, Bluemke D, Burke G, Detrano R, Diez Roux A, Folsom A . Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol. 2002; 156(9):871-81. DOI: 10.1093/aje/kwf113. View

11.

Toblli J, Munoz M, Cao G, Mella J, Pereyra L, Mastai R . ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity (Silver Spring). 2008; 16(4):770-6. DOI: 10.1038/oby.2007.114. View

12.

Komukai K, Mochizuki S, Yoshimura M . Gender and the renin-angiotensin-aldosterone system. Fundam Clin Pharmacol. 2010; 24(6):687-98. DOI: 10.1111/j.1472-8206.2010.00854.x. View

13.

Mantena S, King A, Andringa K, Eccleston H, Bailey S . Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. Free Radic Biol Med. 2008; 44(7):1259-72. PMC: 2323912. DOI: 10.1016/j.freeradbiomed.2007.12.029. View

14.

Kurtz T . Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol. 2005; 42 Suppl 1:S9-16. DOI: 10.1007/s00592-005-0176-0. View

15.

Abbas G, Silveira M, Lindor K . Hepatic fibrosis and the renin-angiotensin system. Am J Ther. 2010; 18(6):e202-8. DOI: 10.1097/MJT.0b013e3181df8df5. View

16.

Lu H, Wu C, Howatt D, Balakrishnan A, Moorleghen J, Chen X . Angiotensinogen Exerts Effects Independent of Angiotensin II. Arterioscler Thromb Vasc Biol. 2015; 36(2):256-65. PMC: 4732917. DOI: 10.1161/ATVBAHA.115.306740. View

17.

Browning J, Szczepaniak L, Dobbins R, Nuremberg P, Horton J, Cohen J . Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40(6):1387-95. DOI: 10.1002/hep.20466. View

18.

Kumagai E, Adachi H, Jacobs Jr D, Hirai Y, Enomoto M, Fukami A . Plasma aldosterone levels and development of insulin resistance: prospective study in a general population. Hypertension. 2011; 58(6):1043-8. DOI: 10.1161/HYPERTENSIONAHA.111.180521. View

19.

Sun K, Su T, Li M, Xu B, Xu M, Lu J . Serum potassium level is associated with metabolic syndrome: a population-based study. Clin Nutr. 2013; 33(3):521-7. DOI: 10.1016/j.clnu.2013.07.010. View

20.

Torabi M, Hosseinzadeh K, Federle M . CT of nonneoplastic hepatic vascular and perfusion disorders. Radiographics. 2008; 28(7):1967-82. DOI: 10.1148/rg.287085067. View